Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6NXR4
UPID:
TTI2_HUMAN
Alternative names:
-
Alternative UPACC:
Q6NXR4; D3DSV7; Q96IM2; Q9H5N4
Background:
TELO2-interacting protein 2 plays a pivotal role as a regulator of the DNA damage response (DDR), integral to the TTT complex. This complex is crucial for stabilizing PIKK family proteins, aiding in cellular resistance to DNA damage from ionizing radiation, UV, and mitomycin C. It also assists in the proper folding of newly synthesized PIKKs alongside HSP90.
Therapeutic significance:
Linked to Intellectual developmental disorder, autosomal recessive 39, TELO2-interacting protein 2's involvement in DDR highlights its potential as a target for therapeutic intervention. Understanding its role could pave the way for innovative treatments for related intellectual developmental disorders.